Clinical Trial Update: Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating sunitinib malate in combination with exemestane for postmenopausal breast cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Sutent (sunitinib)

Snippet

Sponsor: Institut Català d'Oncologia | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN